Study summary
After two earlier pills failed, asciminib worked three times as often as bosutinib
33.8%major molecular response at 3 years, vs 10.5% with bosutinib
What was tested
Asciminib against bosutinib for chronic-phase CML in people who had already tried at least two other tyrosine kinase inhibitor pills.
What they found
- Major molecular response at week 156 was 33.8% vs 10.5%.
- Fewer people stopped asciminib because of side effects (8.3% vs 27.6%).
What it means
Confirmed asciminib as the treatment of choice after two earlier pills.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.